Sponsors (5)
The resolution could improve early detection and treatment access—especially for veterans and other high‑risk groups—but would raise public spending, strain healthcare capacity in underserved areas, and increase the risk of overdiagnosis for some individuals.
At-risk individuals, including veterans, would see expanded screening outreach and earlier lung cancer diagnoses, improving chances of detecting localized disease when 5-year survival is much higher.
Patients and health systems could gain from strengthened research support and justification for funding biomarker testing and targeted therapies, enabling more personalized and effective treatments.
The general public (and families) would benefit from education campaigns raising awareness about lung cancer risk, screening eligibility, and stigma, likely increasing screening participation.
Taxpayers would face higher federal and state healthcare spending to expand screening, diagnostics, and treatment access.
Hospitals, radiology services, and rural communities could experience strain from increased demand for LDCT capacity, follow-up care, and transportation to facilities.
Some screened individuals would face overdiagnosis and false positives, resulting in additional procedures, anxiety, and potential harms from unnecessary follow-up.
Based on analysis of 2 sections of legislative text.
Records congressional findings about lung cancer burden, disparities, low screening rates, and barriers to early detection and care.
Official title: Designating November 2025 as "National Lung Cancer Awareness Month" and expressing support for early detection and treatment of lung cancer.
Introduced December 18, 2025 by Tina Smith · Last progress January 12, 2026
States congressional findings about the scale, causes, disparities, and screening gaps for lung cancer in the United States, citing 2025 estimates for diagnoses and deaths, the role of smoking and secondhand smoke, and racial and veteran disparities. It highlights low screening uptake, barriers to access (facility availability, transportation, awareness, stigma, diagnostic access), and the potential for research and education to improve early detection and outcomes. The measure does not create new programs or funding; it records facts intended to raise awareness about lung cancer incidence, mortality, inequities, and screening shortfalls among the public and policymakers.